Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus LPR
- Development stage
- Unknown
- Lead developer
- Nestlé
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus LPR is a specific probiotic bacterial strain, identified as CGMCC 1.3724, which was developed and extensively researched by Nestlé. It is primarily utilized in infant nutrition and dietary supplements aimed at immune modulation and skin health. Clinical evidence supports its use in reducing the risk and severity of atopic dermatitis in infants when administered to mothers during pregnancy and to infants postnatally. Additionally, it has been investigated for its potential benefits in weight management, where it may influence satiety and metabolic health in adults. The mechanism of action involves the stabilization of the intestinal barrier and the modulation of systemic immune responses, particularly by promoting a balanced Th1/Th2 profile and inducing regulatory T cells to foster immune tolerance.
- Other names
- Lactobacillus rhamnosus strain LPR
02
Targets
EGFR (Epidermal growth factor receptor)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Lactobacillus rhamnosus LPR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus LPR.